PACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pacific Biosciences of California Inc (PACB) is not a good buy for a beginner investor with a long-term focus at this time. The company's financial performance is weak, with significant losses in net income and EPS, and analysts have downgraded the stock with reduced price targets. Additionally, there are no strong technical or proprietary trading signals to suggest immediate upside potential. While there is a positive catalyst in the form of a partnership with Lucid Genomics, the overall sentiment and financial outlook remain unfavorable.
The MACD is positive but contracting, RSI is neutral at 45.438, and moving averages are converging, indicating no clear trend. Key support and resistance levels are pivot at 1.571, R1 at 1.758, and S1 at 1.384. The stock shows limited short-term upside potential with a 40% chance of a 0.1% increase in the next day and 0.29% in the next month.
The partnership with Lucid Genomics to enhance genomic analysis and expand PacBio's ecosystem is a positive development.
Analysts have downgraded the stock to Underweight with reduced price targets, citing competitive pressures and potential demand pauses. Financial performance shows significant declines in net income and EPS.
In Q4 2025, revenue increased by 13.82% YoY to $44.65 million, but net income dropped by -1802.70% YoY to -$40.37 million, and EPS fell by -1400.00% YoY to -0.13. Gross margin improved to 35.26%, up 154.77% YoY.
Barclays downgraded the stock to Underweight with price targets reduced from $2 to $1.50 and then to $1, citing competitive pressures and potential demand pauses in the sequencing space.
